WebJ Clin Oncol 34:953-962. © 2016 by American Society of Clinical Oncology INTRODUCTION Non–small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung … WebFeb 27, 2024 · Malignant pleural effusion (MPE) refers to an abnormal accumulation of fluid and malignant cells or tumor issues in the pleural space. MPE is mainly caused by primary cancers such as lung cancer, breast cancer, lymphomas, or secondary cancer that has metastasized to the pleura. 1,2 The median survival time after diagnosis of MPE ranges …
Symptom Monitoring With Patient-Reported Outcomes During …
WebDurvalumab (MEDI4736), a fully human monoclonal antibody to PD-L1 that blocks the binding of PD-L1 to PD-1 (as well as that to CD80), was evaluated in the pivotal PACIFIC study 19, 20 and was approved in July 2024 in Japan as a consolidation therapy after CCRT for unresectable stage III NSCLC. WebSenan S, Brade A, Wang LH, et al. PROCLAIM: randomized Phase III Trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34:953–962. doi:10.1200/JCO.2015.64.8824 7. unmixed rap vocals
Four-Year Survival With Durvalumab After Chemoradiotherapy in …
WebDec 7, 2015 · A systematic review of controlled trials J Clin Oncol 32: ... 2016 Errata. ... ARTICLE CITATION. DOI: 10.1200/JCO.2015.63.0830 Journal of Clinical Oncology 34, no. 6 (February 20, 2016) 557-565. Published online December 07, 2015. PMID: 26644527. Quick Links. Content. Newest Articles Archive Meeting Abstracts ... WebJun 28, 2024 · J Clin Oncol. 2016; 34: 953-962. Crossref; PubMed; Scopus (294) Google Scholar; For patients not cured with, or not eligible for adjuvant durvalumab, new … WebMay 20, 2016 · Patients and methods: This phase I, nonrandomized, open-label, dose-escalation trial used a 3 + 3 dose-escalation scheme and included patients with advanced solid tumors. Intravenous LY2606368 was dose escalated from 10 to 50 mg/m (2) on schedule 1 (days 1 to 3 every 14 days) or from 40 to 130 mg/m (2) on schedule 2 (day 1 … unm it officers